Podcasts about mycobacterial

In this podcast, I talk about how the disease tuberculosis, can be caused by a number of different Mycobacterial species, and how diagnosing the right one is vital to get the right treatment. All my posts have links to online resources that you might find useful, and you can find the link to this particular blog here⁠⁠.

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Anti-Mycobacterial Drugs⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Microbiology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

Dr. Anthony Cannella, Associate Professor of Medicine at the University of South Florida Division of Infectious Diseases, presents this update on nontuberculous mycobacterial (NTM) infections. Dr. Cannella begins by discussing the taxonomy of nontuberculous mycobacteria. Next, he reviews epidemiology including the common methods of transmission of the infection. He then describes the immunological factors that confer increased susceptibility for certain individuals. Laboratory growth characteristics are also reviewed. Dr. Cannella then reviews the most significant species of NTM producing disease in humans. He begins by describing Mycobacterium avium complex, and then discusses M. kansasii, M. xenopii, M. haemophilum, S. szulgai, and M. marinum. Clinical cases are presented throughout the talk to help with information retention and provide specific clinical examples.

There is an increasing awareness of non-tuberculous mycobacterium (NTM) disease as our populations ages and survival increases in chronic diseases due to new medical advances. NTM infections are often challenging to diagnose unless you are thinking about them as a possibility in your differential diagnosis. Therefore, there is an urgent need to identify population subgroups that are at increased risk for NTM infections. In this edition of the JIM podcast, Drs. Stephanie Baers and Sarah Tran discuss their recent manuscript: Non-tuberculous mycobacterial infections in patients with end-stage renal disease: Prevalence, risk factors, and mortality which can be found in the October 2023 issue of JIM.

In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G 

In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G

Welcome to Febrile's Curious Congenital Conundrums Part 2!! Drs. Amedine Duret and Liz Whittaker kick off the series with the first episode featuring a mycobacterial malady affecting mother and baby!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.com

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Go online to PeerView.com/WCS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life. Upon completion of this activity, participants should be better able to: Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis; Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care; and Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Nontuberculous mycobacteria (NTM) infections are ten times more prevalent than tuberculosis infections, affecting primarily the elderly and immunocompromised. Bryan Garcia, MD, a pulmonologist, discusses the likely origins of NTM, who is most at risk to be infected by these ubiquitous bacteria, and the criteria for diagnosis. Learn why NTM needs to be better accounted for at both the epidemiological and clinical levels in the future.

Mike Rinder ran Scientology's intelligence agency for years. He worked directly for Ron Hubbard and for David Miscavige. Mike talks about his dedication to Scientology and the complex network of circumstances that made him a true believer willing to harass and try to destroy critics of Scientology. Mike shows how a decent, compassionate, intelligent person can become the tool of an unscrupulous authoritarian cult leader. to read Jon's paper, never believe a hypnotist or watch the video for more about scrofula - Mycobacterial cervical lymphadenitis no ants were harmed in the making of this video.

This podcast episode is part of a multimedia program reviewing the management of nontuberculous mycobacterial lung disease (NTM-LD). Tune in to hear Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC, and Anne O'Donnell, MD, highlight the diagnostic criteria and optimal treatment strategies in patients with NTM-LD. The overview will include: Recommended assessments and tests to appropriately diagnosis NTM-LD in patientsA summary of the current guidelines for the management of NTM-LD, including appropriate monitoring of medications.Guidance on how to individualize treatment plans for patients with NTM-LD based on disease and patient characteristicsPresenters: Jennifer Faber-Gerling, RN, MS, CNS, ANP-BCNurse PractitionerDivision of Mycobacterial and Respiratory InfectionsNational Jewish HealthDenver, ColoradoAnne O'Donnell, MDProfessor of MedicineDivision of Pulmonary, Critical Care, and Sleep MedicineGeorgetown University Medical CenterWashington, DCTo view other program offerings, including a CE-certified on-demand webcast, a Q&A text module, and to download slides, visitpce.is/NTM.

Infections caused by Mycobacterium abscessus appear to be increasing in frequency among the immunocompromised population and are challenging to treat. Antibiotic options in these cases are scarce, prologued therapy is required and new options are needed. We will discuss this important topic with experts in the field. Topics discussed: Define M. abscessus as an opportunistic pathoge The intrinsic phenotypic characteristics of M. abscessus, including resistance to common antimicrobials Treatment approaches and rationale for these strategies Guests: Kelly Dooley, MD. PhD, MPH.  Professor of Medicine, Johns Hopkins University and Editor of AAC Charles L. Daley, MD, Professor and Chief of the Division of Mycobacterial and Respiratory Infections. National Jewish Health Thomas Dick, PhD. Professor, Center for Discovery and Innovation, Hackensack Meridian Health This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, decrease disease burden, and optimize patient outcomes.

This episode is also available as a blog post: http://biopatrika.com/2021/04/27/interview-mycobacterial-histidine-biosynthesis-infection-tuberculosis/

In this podcast, expert clinicians will discuss treatment for a patient with refractory Mycobacterium avium complex lung disease despite many months of guidelines-based therapy.    For CME Credit, complete activity here: https://tinyurl.com/LungMET2

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.10.13.337667v1?rss=1 Authors: Bao, Y., Zhang, Q., Wang, L., Aguilera, J., Vazquez Reyes, S., Sun, J. Abstract: EsxA has been recognized as an important virulence factor of Mycobacterium tuberculosis (Mtb) that plays an essential role in Mtb cytosolic translocation by penetrating phagosomal membranes with its acidic pH-dependent membrane permeabilizing activity (MPA). Currently, the reported cytolytic activity of EsxA at neutral pH is controversial. In this study we have obtained direct evidence that it is the ASB-14, a detergent used in EsxA purification, but not EsxA that causes cytolysis at neutral pH. We have also found that the exogenously added EsxA was internalized into lung epithelial cells (WI-26) and inserted into the host membranes, and these processes could be blocked by cytochalasin D and bafilomycin A. This indicates that EsxA is bound by host surface receptors and internalized into acidic endosomal compartments. This observation has intrigued us to investigate the role of EsxA in mycobacterial adherence and invasion in host cells. Interestingly, compared to the Mycobacterium marinum (Mm) wild type strain, the Mm strain with deletion of the esxBA operon (MmEsxA:B) had a lower adherence but a higher invasion in WI-26 cells. More interestingly, either inducible knockdown of EsxAB or removal of the bacterial surface-associated EsxAB by Tween-80 exhibited opposite results compared to gene knockout. Finally, the surface-associated EsxA is correlated to mycobacterial virulence. Together, the present study has shown for the first time that EsxA is internalized into the host cells and inserts into the host membranes, and mycobacterial surface-associated EsxAB plays an important role in mycobacterial adherence and invasion in host cells, which warrants further investigation. Copy rights belong to original authors. Visit the link for more info

Granulomatous neck masses are rather common. The differential diagnosis here includes mycobacterial adenitis, sarcoidosis, and cat-scratch disease due to Bartonella henselae. The incidence of mycobacterial lymphadenitis, however, is on the rise among both immunocompromised and immunocompetent individuals. The usual presentation of granulomatous disease in the neck is simply single or matted nodes. Although mycobacterial adenitis can extend to the skin and drain externally, this presentation is rather rare. FNA biopsy is usually the best initial diagnostic approach. Here, cytology, a smear for acid-fast bacilli, a mycobacterial culture, and a sensitivity test can all be done. PCR from FNA is the most sensitive test and is particularly useful when conventional methods have not been diagnostic but the practitioner's clinical impression remains consistent for tuberculosis infection. While FNA has a high sensitivity (about 88%), its specificity is low (49%) and an excisional biopsy is often required to confirm the diagnosis. For atypical lymphadenopathy, treatment depends on the sensitivity results of the culture. Antibiotics, however, such as isoniazid (six months standard dosage) and rifampin (two months of the standard dosage) tend to be effective. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

In this episode, we talk about non-tuberculous mycobacterial infections - the most common of which is Mycobacterium Avium Complex (MAC) in North America. Dr. Jessica Kapralik - Respirology Fellow, takes us through the tricky diagnosis, work-up and helps clarify when and who to treat for these often insidious infections.  

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.27.269936v1?rss=1 Authors: Bukhdruker, S., Varaksa, T., Grabovec, I., Marin, E., Shabunya, P., Kadukova, M., Grudinin, S., Kavaleuski, A., Gusach, A., Gilep, A., Borshchevskiy, V., Strushkevich, N. Abstract: Spreading of the multidrug-resistant (MDR) strains of the deadliest pathogen Mycobacterium tuberculosis (Mtb) generates the need for new effective drugs. SQ109 showed activity against resistant Mtb and already advanced to Phase II/III clinical trials. Fast SQ109 degradation is attributed to the human liver Cytochrome P450s (CYPs). However, no information is available about interactions of the drug with Mtb CYPs. Here, we show that Mtb CYP124, previously assigned as a methyl-branched lipid monooxygenase, binds and hydroxylates SQ109 in vitro. A 1.25-[A] resolution crystal structure of the CYP124-SQ109 complex unambiguously shows two conformations of the drug, both positioned for hydroxylation of the {omega}-methyl group in the trans position. The hydroxylated SQ109 presumably forms stabilizing H-bonds with its target, i.e., the Mycobacterial membrane protein Large 3 (MmpL3). We anticipate that Mtb CYPs could function as analogs of drug-metabolizing human CYPs affecting pharmacokinetics and pharmacodynamics of antitubercular (anti-TB) drugs. Copy rights belong to original authors. Visit the link for more info

Professor Graham Hatfull studies bacteriophages in the human body; these are viruses that infect bacteria. Interested in both "the exploration and exploitation of these" bacteriophages infecting bacteria, he explains Why his lab has focused on mycobacterium characteristics and the mycobacteria phages that target this group, How the coevolution of bacteria and phages have created a complex relationship affecting the molecular genetics of bacteria, and What happened in a case study utilizing a combination of phages to kill a particular strain of Mycobacterium abscessus in a Cystic Fibrosis patient. Graham Hatfull is the Eberly Family Professor of Biotechnology in the Department of Biological Sciences at the University of Pittsburgh and an HHMI Professor. He tells listeners about the basics and the complexities of phages and potential therapies that might utilize them.  He explains that his lab has focused mainly on the mycobacterium group because it contains important human pathogens like Mycobacterium tuberculosis, which is responsible for the symptoms and spread of tuberculosis. Tuberculosis causes around 1.7 billion deaths a year. Studying the phages that infect this group of mycobacterium helps understand such pathogens as well as potential treatments. In order to study these phages, his lab uses bacterium related to these more dangerous bacteria as safer surrogates. This work puts us them a good position to figure out which phages infect TB and which ones don't. He also describes phage biology and coevolution with bacteria, which has led to a complex relationship. For example, he discusses phages that are "temperate," and what that means in relationship to bacteria development. Finally, he talks about a successful case study in which they were able to use a cocktail of phages to successfully kill a particular strain of Mycobacterium abscessus in a Cystic Fibrosis patient. For more, see his lab's website at hatfull.org. Available on Apple Podcasts: apple.co/2Os0myK

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.06.225375v1?rss=1 Authors: Guo, H., Courbon, G. M., Bueler, S. A., Mai, J., Liu, J., Rubinstein, J. L. Abstract: Tuberculosis (TB), the leading cause of death by infectious disease worldwide, is increasingly resistant to first line antibiotics. Developed from a screen against Mycobacterium smegmatis, bedaquiline can sterilize even latent M. tuberculosis infections that may otherwise persist for decades and has become a cornerstone of treatment for multidrug resistant and extensively-drug resistant TB. Bedaquiline targets mycobacterial ATP synthase, an essential enzyme in the obligate aerobic Mycobacterium genus. However, how the drug binds the intact enzyme is unknown. We determined the structure of M. smegmatis ATP synthase with and without bedaquiline. The drug-free structure reveals hook-like extensions from the enzyme's subunits that inhibit ATP hydrolysis in low-energy conditions, such as during latent infections. Bedaquiline binding induces global conformational changes in ATP synthase, creating tight binding pockets at the interface of subunits a and c. These binding sites explain the drug's structure-activity relationship and its potency as an antibiotic for TB. Copy rights belong to original authors. Visit the link for more info

Go online to PeerView.com/GRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

Go online to PeerView.com/GRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

Go online to PeerView.com/GRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

Go online to PeerView.com/GRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this program, a hematology-oncology expert discusses recent advances in multiple myeloma treatment, including highlights from the 2020 American Society of Clinical Oncology Annual Meeting. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma according to transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

Dr. Paul Saleeb, Assistant Professor of Medicine, from the Division of Infectious Diseases presents on non tuberculous infections focusing on pulmonary manifestations of nocardia and actino infections.

Infectious disease is getting a lot of attention right now because we are in the middle of the Corona Virus pandemic. In this episode (recorded back in January),  Dr. Molly Matty helps us explore how Zebrafish, a model organism for development is being used to investigate host pathogen interactions, specifically with Mycobacterium marinum.  Other species of Mycobacterium cause tuberculosis or leprosy in humans, of course. Molly explains the benefits of the zebrafish model for potentially identifying host derived therapies for Mycobacterial diseases. In particular, zebrafish: Can be engineered with fluorescently labeled vasculature and macrophages Readily absorb small molecules (like antibiotics) Are transparent as larvae and embryos All of which make them amenable to direct observation of pathogen interactions under a microscope. Bonus: Molly explains how to inject a live zebrafish without a mask and snorkel.   Learn more at: mollymatty.com Connect on Twitter: @ooomollypop  

Mycobacterial infections after breast augmentation is extremely rare. Found out how one centre had 10 cases in just 5 months and why a Jacuzzi was so important in cracking the case! Scheflan M, Wixtrom RN. Over Troubled Water: An Outbreak of Infection Due to a New Species of Mycobacterium following Implant-Based Breast Surgery. Plast Reconstr Surg. 2016 Jan;137(1):97-105

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

Go online to PeerView.com/FBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nontuberculous mycobacterial lung disease reviews the latest efficacy and safety data presented at the 2019 American Thoracic Society International Conference and offers insight on individualizing treatment plans for patients with nontuberculous mycobacterial lung disease (NTM-LD). Upon completion of this activity, participants should be better able to: Describe the increasing medical burden of NTM-LD, particularly in the population older than age 65, Discuss the latest efficacy and safety data for novel therapies and updates to diagnostic and management guidelines for NTM-LD, Apply late-breaking data to individualized treatment plans for patients with NTM-LD.

At ASM Microbe in San Francisco, Nels and Vincent meet up with Paul Turner to talk about evolutionary considerations in using bacteriophages to treat infections with antibiotic-resistant bacteria. Hosts: Nels Elde and Vincent Racaniello Guest: Paul Taylor Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiEVO Turner Lab at Yale Phage therapy: A renewed approach (Cell Host Microbe) Phage treatment of aortic graft (Evol Med Pub Health) Time stamps by Jolene. Thanks! Science Picks Nels- Science Glass Vincent- Phage therapy for disseminated Mycobacterial infection Music on TWiEVO is performed by Trampled by Turtles Send your evolution questions and comments to twievo@microbe.tv

En nuestro programa de esta semana hablamos de las dificultades de tratamiento de las infecciones causadas por M. abscessus. Referencias:   Rebekak M. Dendrick y colaboradores. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature med 2019; 25: 730-733. h Keenan Ryan y Thomas Byrd. Mycobacterium abscessus: Shapeshifter of the Mycobacterial World. Front Micorbiol Nov 2018.   Benwill, Jeana L. and Wallace, Richard J. Jr. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Op Infect Dis Dec 2014; 27: 506-510.    La Frase de la Semana: La tomamos de la obra “A Raisin in the Sun” A Raisin in the Sun es una obra de Lorraine Hansberry que debutó en Broadway en 1959. Lahistoria narra las experiencias de una familia negra en una versión ficticia de la subdivisión de Washington Park en el vecindario Woodlawn de Chicago, mientras intentan mejorar sus circunstancias financieras luego de la muerte del padre. ElNew York Drama Critics Circle la nombró la mejor obra de teatro de 1959. La frase dice: “Cuando empieces a medir a alguien, mídelo bien ... Asegúrate de haber terminado de tomar en cuenta las colinas y los valles queatravesó antes de llegar a donde sea que esté”  

Non-tuberculous mycobacterial lung disease is particularly vexing for clinicians to diagnose and treat. George Solomon, MD discusses emerging treatments as well as the guidelines for diagnosis and management.

Welcome to the first official Pediatric Research Now Podcast, an interview with Dr. Stacey Martiniano of Children's Hospital Colorado. She discusses recent research on the treatment of non-tuberculous mycobacterial infections in patients with cystic fibrosis. Check out PRN's summary of the study.   Pediatric Research Now highlights examples of the latest articles in pediatric research from around the United States and around the world. Our expert faculty at Ann & Robert H. Lurie Children’s Hospital translate the findings and publish easy-to-digest summaries for health professionals on the go. All content, including our newsletters, is cost-free.  The PRN Podcast takes things a step beyond and digs in to the stories behind the studies. We want to know the inspirations, the challenges, the unexpected outcomes and the future implications associated with recent journal publications... as told by the investigators themselves.

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Go online to PeerView.com/PGE860 to view the entire program with slides. In this activity, an expert in lung disease discusses the increased incidence and prevalence of nontuberculous mycobacterial lung disease (NTM-LD) and the risk factors for developing NTM-LD while offering insights into the recognition of NTM-LD, the challenges associated with managing this condition, and the potential role of novel therapeutic strategies. The activity will focus on the overall goal of diagnosing NTM-LD earlier to ensure that patients benefit from timely and appropriate treatment leading to the best possible outcomes. Upon completion of this activity, participants will be able to: Identify strategies to optimally diagnose NTM-LD, including reducing time to diagnosis, rapid identification of risk factors, and utilization of clinical, radiographic, and microbiologic criteria, Cite recent evidence on the medical burden of NTM-LD and emerging therapeutic strategies, including data from registries, epidemiological studies, health outcomes, and clinical trials, Recognize best practices in NTM-LD treatment, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Employ individualized, guideline-concordant approaches to treat patients with NTM-LD, taking into account strategies to optimize medication adherence, manage adverse events, and integrate newer therapies into clinical management.

Dr. Sandin provides a general overview of identification techniques for Mycobacterial organisms. He discusses and outlines classification systems for the Mycobacteria that are human pathogens. He then discusses laboratory stains that are useful in identifying Mycobacteria and reviews other diagnostic methods which have become essential to Mycobacterial species identification, including the various nucleic amplification-based methods. Various pathology pearls of Mycobacterial identification are also mentioned. Lastly, he discusses two clinical cases involving acid fast organisms.

Bill Jacobs talks about developing mycobacterial genetic tools and using them to discover ways to shorten TB treatment. He also talks about the SEA-PHAGES program that allows high-school students to participate in phage discovery. Host: Julie Wolf Subscribe (free) on iPhone, Android, RSS, or by email. You can also listen on your mobile device with the ASM Podcast app. Julie's biggest takeaways: The challenges of working with an easily aerosolized bacterium are aided by complementary studies on a noninfectious relative. M. smegmatus doesn’t colonize mammals and grows slower, giving researchers the opportunity to acclimate themselves to working with mycobacterial cultures. Jacobs was the first scientist to introduce DNA into M. tuberculosis using a phasmid - part plasmid, part mycobacterial phage. The first phage came from Jacobs’ dirt yard in the Bronx, so he named it BxB1 for the Bronx Bomber. Another phage, TM4, became the workhorse phasmid when Jacobs cloned an E. coli cosmid sequence into a nonessential part of the phage genome. It replicates in E. coli as a plasmid but becomes a phage inside Mycobacteria, facilitating manipulation. The shuttle phasmids allowed transposon delivery to make transposon libraries, and the creation of gene knockouts. To this day, we use Ziehl-Neelsen staining to differentiate acid-fast mycobacteria from gram-positive or gram-negative bacteria - the mycolic acids on the outer part of the envelope make up some of the longest microbial lipid chains. But mycobacteria can regulate its acid-fast positive or negative status; the acid-fast negative organisms are a persistent population that are often ignored inside of patients. 99.99% of M. tuberculosis bacteria are not persistent, but the last 0.1% have entered into a persistent state expressing many stress proteins that help them become refractory to killing. A normal course of antibiotic chemotherapy for patients is six months. If infected with a strain resistant to the two frontline drugs, that time goes up to two years. The problem is even greater in extremely multidrug resistant (XDR) strains. What we really need is a way to understand persistence and a way to shorten chemotherapy. That’s why were were absolutely amazed when we discovered that cysteine with isoniazid completely sterilizes Mtb cultures in vitro and in vivo! The culture is sterilized because the bacteria can’t form persisters. Vitamin C co-treatment with antibiotics may lead to a shortened course of therapy for TB treatment. Neutralizing antibodies to the herpesvirus glycoprotein have been the dogma for protecting from herpes. Jacobs and his colleagues discovered that a vaccine based on a glycoprotein-knockout virus confers sterilizing immunity not through neutralizing antibodies but through antibody-dependent cell cytoxicity (ADCC). This ADCC response may also be important to develop a more effective TB vaccine.   Featured Quotes (in order of appearance): “You’ll never know how bad your aseptic technique is until you start working with tuberculosis!” “I think part of the reason I had the opportunity to develop genetics for TB - it’s not like it wasn’t important to do - but a lot of people were disappointed when working with the organism.” “We’re about to take TB genetics to where yeast genetics is.” “One of the tubicle bacilli’s greatest powers or one of its most important phenotypes is that it has the ability to persist, which means it has the ability to tolerate killing effectors, either killing by the immune system or killing by bactericidal drugs.” “I took students to the Bronx Zoo, and over by the zebra pen, I sniffed and said ‘I smell a phage!’ In fact, that’s not crazy - anyone who plants flowers knows what good soil smells like, and in the good soil, you’re smelling the bacteria that live in the soil, the Streptomyces and Mycobacteria. I reached down and grabbed that dirt, and when we went back to work we isolated BxE1.” “I’ve never met a phage I wasn’t excited about!” “I now believe that most pathogens do not ‘want’ ADCC antibodies to be made, and they have immune evasion strategies where they skew the immune response to get the wrong antibodies. Since the time we published our first paper, numerous groups have shown that correlates of protection for HIV, for influenza, and for Zika, turn out to be ADCC antibodies.” “Genetics is the mathematics of biology!”   Links for this episode Bill Jacobs lab site NYTimes story on 1993 rapid diagnostic test using luciferase AACJournal: Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampicin in mice Cell: Origins of highly mosaic mycobacteriophage genomes SEA-PHAGES program eLife: Whole genome comparison of a large collection of mycobacteriophages reveals a continuum of phage genetic diversity mBio: Dual-reported mycobacteriophages (Φ2DRMs) reveal preexisting Mycobacterium tuberculosis persistent cells in human sputum Tuberculosis - Its cause, cure and prevention [1914] (pdf)   Send your stories about our guests and/or your comments to jwolf@asmusa.org.  

Dr. John Fleetham sits down with Dr. Kennth Olivier to discuss the findings of his paper published in the AJRCCM this past March

TSRA Podcast: Thoracic - Treatment Of Mycobacterial Lung Infections(Jordan Hoffman & John Mitchell) by TSRA

We talk to Mycobacterial legend Bill Jacobs, the creator of shuttle phasmids, the developer of the beloved smeg strain mc²155, and the twin brother of our very own Debbie Jacobs-Sera. Bill talks about how he got into science, his past Mycobacterial work, a potential vaccine for Herpes, and armadillos.

We talk to Mycobacterial legend Bill Jacobs, the creator of shuttle phasmids, the developer of the beloved smeg strain mc²155, and the twin brother of our very own Debbie Jacobs-Sera. Bill talks about how he got into science, his past Mycobacterial work, a potential vaccine for Herpes, and armadillos.

Treatment of Pulmonary Nontuberculous Mycobacterial Infections: Many Questions Remain

Volume 3, Issue 12.Case studies offer opportunity to differentiate the needs of each patient when managing respiratory infections. Dr. Elliott Dasenbrook will review the prevalence of important CF organisms over the last 10 years, the impact of respiratory tract MRSA on survival, the association between a virulent strain of P. aeruginosa that can spread among patients and lung transplant or death, as well as the impact of chronic non-tuberculous Mycobacterial lung disease on lung function.The post Featured Cases: Emerging Pathogens in Cystic Fibrosis appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information.

Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist.  His particular interest lies in mycobacterial and fungal diseases, including tuberculosis.  In his work, Mr. Guruswamy places a lot of emphasis on helping others.  A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis.  Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results.  Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket.  In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career.

Guest: Gwen Huitt, MD Host: Lee Freedman, MD Dr. Huitt discusses the range of atypical mycobacterial infections encountered in practice. She emphasizes the settings in which these infections present, how a diagnosis can be made and how they should be treated and followed.

Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.

Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.

Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.

Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.

Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.

Go online to PeerView.com/SVG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in NTM-LD discusses diagnosing and treating a patient with NTM-LD, with the goal of maintaining treatment adherence. Upon completion of this activity, participants should be better able to: Describe the burden of treatment associated with nontuberculous mycobacterial lung disease (NTM-LD), especially adverse events that may lead to patient discontinuation of therapy, Discuss the latest evidence-based recommendations for the treatment of NTM-LD, including airway clearance, medication optimization, susceptibility testing, repeated cultures, and duration of treatment, Develop treatment plans for patients with NTM-LD based on the latest ATS/IDSA guidelines, disease severity, patient needs and preferences, and the latest clinical evidence on efficacy and safety, Apply strategies to manage adverse events associated with treatment of NTM-LD in order to maintain patient adherence to therapy and improve outcomes.